CAS: 122852-42-0; Alosetron

该化合物是一种选择性的血清素素 5-HT3受体对抗体,主要用于治疗有严重症状的妇女的肠胃肠胃炎综合症(IBS),通过调节胃肠道中的血清素活动,从而减少肠道运动力,减轻腹部疼痛和腹泻等症状.奥洛塞坦的特点是化学配方,包括碳,氢,氮和氧等元素.该物质一般是口服的,具有特定的药用动力特征,包括吸收,分配,代谢和影响其治疗功效和安全的排泄物特征.由于其行动机制,热心器可以产生副作用,包括内分泌和潜在的严重胃肠并发症,这就需要仔细选择和监测病人.重要的是要注意,对于索洛松子,它必须接受监管,并且是在特定条件下规定,以减少其使用的风险.

结构式图片

上下游产品

4-hydroxymethyl-5-methylimidazole hydr°Chloride sodium hydrogencarbonate 2,3,4,5-tetrahydro-5-methyl-1H-pyrido[4,3-b]indol-1-one 4-chloromethyl-5-methyl-1-tritylimidazole

合成工艺路线路线简述

    2,3,4,5-Tetrahydro-2-Tosyl-1H-Pydrido[4,3-B]Indole-1-One置于甲烷磺酸,Sodium Anthracenide,Potassium Carbonate体系中,用 N-甲基吡咯烷酮,乙二醇二甲醚,N,N-二甲基甲酰胺 用作溶剂,化学反应 24.5H,反应生成阿洛司琼
    参考文献:二氧化碳对2-炔基苯胺的环状抗氮杂羧化反应
    标题:二氧化碳对2-炔基苯胺的环状抗氮杂羧化反应
    摘要:直接抗2-Alkynylanilines用co-Azacarboxylation 2由znet介导2中观测到,得到吲哚-3-羧酸,一类用于许多生物活性化合物的合成中的重要化合物,有效地在1大气压的co 2.不同原料的容易获得的性质以及对各种官能团的耐受性为有效构建图1中列出的生物活性化合物的多样化文库提供了巨大的机会.例如,该方法已用于合成lotronex(一种药物)用于治疗肠易激综合症的分子.
    Doi:10.1021/acs.Orglett.6B00884

    海关参考信息

    专利信息


    专利号:US-8889897-B2
    优先权日:2011-12-23
    标 题:Electrocarboxylation synthesis for obtaining intermediates useful for the synthesis of SPAN derivatives
    发明人:OSSO J ORIOL; VEGA LOURDES F; GALLARDO ILLUMINADO; GUIRADO GONZALO; GOMEZ ANA BELEN; RECHE FRANCISCA IRENE
    权利人:AIR PROD & CHEM
    摘要:The present invention relates to a process for obtaining a compound of formula (1), (2) or (3) by means of a electrocarboxylation with CO 2 . The present invention also relates to the new intermediates (1) and (2). The present invention further relates to the use of intermediates (1) and (2) as starting materials for the synthesis of SPAN derivatives.

    专利号:US-2025206743-A1
    优先权日:2022-03-25
    标 题:Tyk2 inhibitor synthesis and intermediates thereof
    发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
    权利人:TAKEDA PHARMACEUTICALS CO
    摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

    专利号:US-7807349-B2
    优先权日:2002-11-29
    标 题 :Protein synthesis monitoring (PSM)
    发明人:SMILANSKY ZEEV
    权利人:ANIMA CELL METROLOGY
    摘要:A method and a device are disclosed for monitoring the synthesis of proteins by the ribosome in real time, in vivo as well as in in-vitro. The ribosome is engineered to carry a donor fluorophore, and tRNA and/or amino acids and/or some other part of the ribosome are either engineered to carry acceptor fluorophores or else their natural fluorescent properties are utilized as acceptors. As the ribosomes mechanism processed the mRNA and tRNA molecules and synthesizes a polypeptide chain, a light source illuminates the ribosome, exciting the donor fluorophores and thereby the acceptor fluorophores whenever these are in sufficient proximity to a donor. The resulting signals are detected and used as a key for real-time database searching and identification of the protein being synthesized. The resulting data can be tabulated and interpreted in different ways. FIG. ( 1 ) describes the properties of a FRET pair and the dependence of FRET on pair distance.

    专利号:US-8442773-B2
    优先权日:2002-11-29
    标题:Protein synthesis monitoring (PSM)
    发明人:SMILANSKY ZEEV
    权利人:SMILANSKY ZEEV; ANIMA CELL METROLOGY
    摘要:A method and a device are disclosed for monitoring the synthesis of proteins by the ribosome, wherein the ribosome is bound to a first label, for example a donor fluorophore, and a tRNA and/or amino acid are is bound to a second label, for example an acceptor fluorophore, wherein the first and second labels together from a FRET pair. As the ribosome mechanism processes the mRNA and tRNA molecules and synthesizes a polypeptide chain, a light source illuminates the ribosome, exciting the donor fluorophores and thereby the acceptor fluorophores whenever these are in sufficient proximity to a donor. The resulting signals are detected and used as a key for database searching and identification of the protein being synthesized.

    专利号:US-2008280855-A1
    优先权日:2005-06-22
    标 题 :Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles
    发明人:CHIESA MARIA VITTORIA; PALMER ANDREAS; BUHR WILM; ZIMMERMANN PETER JAN; BREHM CHRISTOF; SIMON WOLFGANG-ALEXANDER; POSTIUS STEFAN; KROMER WOLFGANG; ZANOTTI-GEROSA ANTONIO
    权利人:NYCOMED GMBH
    摘要:The invention relates to a process for the synthesis of compounds of the formula 1-a and compounds of the formula 1-b. n n n n n n n n n n The compounds of the formula 1-a and the compounds of the formula 1-b, in which the substituents R1, R2, R3, and Ar have the meanings indicated in the description, are valuable intermediates for the preparation of pharmaceutically active compounds.

    专利号:US-2013165684-A1
    优先权日:2011-12-23
    标题:Electrocarboxylation Synthesis for Obtaining Intermediates Useful for the Synthesis of SPAN Derivatives
    江苏永达药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.yongdachina.com
    电话: 0519-85777058👤
    📞江苏永达药业有限公司 ⚠️参考联系方式

    销售电话:0519-85777058
    邮箱:info@yongdachina.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Motavallian A, Minaiyan M, Rabbani M, Mahzouni P, Andalib S. Anti-inflammatory effects of alosetron mediated through 5-HT(3) receptors on experimental colitis. Res Pharm Sci. 2019 Jun;14(3):228-236. doi: 10.4103/1735-5362.258489.
    2: Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Curr Med Res Opin. 2019 Mar;35(3):461-472. doi: 10.1080/03007995.2018.1533456. Epub 2018 Nov 22. doi: 10.1177/1756284818771674. eCollection 2018.

    合成参考文献


    参考文献:10.1046/j.1365-2036.2002.01252.x
    摘要:Clemens CH, Samsom M, Van Berge Henegouwen GP, Fabri M, Smout AJ. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2002 May;16(5):993–1002. doi: 10.1046/j.1365-2036.2002.01252.x.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知